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Abstract
Background: Evaluation of changes in tumor size from images acquired by ultrasound (US), computed
tomography (CT) or magnetic resonance imaging (MRI) is a common measure of cancer chemotherapy efficacy.
Tumor size measurement based on either the World Health Organization (WHO) criteria or the Response Evaluation
Criteria in Solid Tumors (RECIST) is the only imaging biomarker for anti-cancer drug testing presently approved by
the United States Food and Drug Administration (FDA). The aim of this paper was to design and test a quality
assurance phantom with the capability of monitoring tumor size changes with multiple preclinical imaging
scanners (US, CT and MRI) in order to facilitate preclinical anti-cancer drug testing.
Methods: Three phantoms (Gammex/UTHSCSA Mark 1, Gammex/UTHSCSA Mark 2 and UTHSCSA multimodality
tumor measurement phantom) containing tumor-simulating test objects were designed and constructed. All three
phantoms were scanned in US, CT and MRI devices. The size of test objects in the phantoms was measured from
the US, CT and MRI images. RECIST, WHO and volume analyses were performed.
Results: The smaller phantom size, simplified design and better test object CT contrast of the UTHSCSA
multimodality tumor measurement phantom allowed scanning of the phantom in preclinical US, CT and MRI
scanners compared with only limited preclinical scanning capability of Mark 1 and Mark 2 phantoms. For all
imaging modalities, RECIST and WHO errors were reduced for UTHSCSA multimodality tumor measurement
phantom (≤1.69 ± 0.33%) compared with both Mark 1 (≤ -7.56 ± 6.52%) and Mark 2 (≤ 5.66 ± 1.41%) phantoms.
For the UTHSCSA multimodality tumor measurement phantom, measured tumor volumes were highly correlated
with NIST traceable design volumes for US (R
2 = 1.000, p < 0.0001), CT (R
2 = 0.9999, p < 0.0001) and MRI (R
2 =
0.9998, p < 0.0001).
Conclusions: The UTHSCSA multimodality tumor measurement phantom described in this study can potentially be
a useful quality assurance tool for verifying radiologic assessment of tumor size change during preclinical anti-
cancer therapy testing with multiple imaging modalities.
Background
Highly consistent, reproducible and standardized
response criteria are essential to evaluate the efficacy of
new anti-cancer drugs in multicenter trials [1]. The
World Health Organization (WHO) criteria and the
Response Evaluation Criteria in Solid Tumors (RECIST)
have been widely used as the only imaging biomarker
presently approved by the United States Food and Drug
Administration (FDA) for drug testing, although the use
of functional imaging methods such as Positron
Emission Tomography (PET) Response Criteria in Solid
Tumors (PERCIST) complements the limitations of ana-
tomic methods in treatment response assessment in
terms of biological relevance and prognostic information
[2-4]. The criteria require either two dimensional
(WHO criteria- sum of the product of greatest perpen-
dicular dimensions in the transverse plane over all target
lesions) or one dimensional (RECIST - sum of single
longest dimensions in the transverse plane for arbitrary
five lesions per organ and up to ten lesions per patient)
tumor size measurements [1,4-12]. Three-dimensional
radiologic assessment of tumor burden also has been
performed using volumetric techniques [13,14].
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tomic measurement have been developed for assess-
ment with computed tomography (CT) and magnetic
resonance imaging (MRI) [15-22]. However, the devel-
opment of these phantoms has predominately focused
on clinical assessment. Yet, in recent years, there has
been an emphasis to improve preclinical anti-cancer
drug testing by incorporating longitudinal imaging of
tumor models with use of preclinical scanners specially
designed for small rodents [23-25]. A tumor measure-
ment QA phantom for preclinical studies in rodent
models could be used to identify and correct biased
measurement results for tumor size determined with
different imaging modalities in multiple laboratories or
institutions [26]. In addition, the verification for radi-
ologic assessment of tumor size change using this QA
phantom would allow standardization of imaging pro-
tocols prior to animal studies, thus potentially reducing
the number of animals required, increasing study effi-
ciency and decreasing cost.
This Technical Advance describes the evolution in
design, construction and testing of a multimodality QA
phantom for use with preclinical scanners. Initial design
attempts modified commercial phantoms available for
human testing. By using the results from these early
versions, the UTHSCSA multimodality tumor measure-
ment QA phantom was successfully constructed for
further quality assurance testing of tumor size in rodent
models.
Methods
Gammex/UTHSCSA Mark 1 phantom
In 2007, the Gammex 404 GS LE phantom was modified
in an attempt to construct the first generation tumor
measurement phantom and this new phantom was
denoted as Gammex/UTHSCSA Mark 1 phantom (Fig-
ure 1 a and 1b, Table 1). The phantom was composed
of four sets of measurement calibration standards: A.
Image Caliper - stainless steel wires at 2 mm vertical
intervals and 3 mm horizontal intervals, B. Volume -
two spheres with volumes 179.59 and 523.59 mm
3,C .
Diameter - long cylinder (5 to 10 mm by 0.5 mm inter-
vals) and D. Diameter Depth Dependence - 2 mm-cylin-
ders from 2 to 15 mm depth.
US, CT and MR images of the phantom were obtained
following the imaging protocols listed in Table 2 (Figure
1 c-e). The size of test objects in the phantom was mea-
sured three times independently. For US, visual mea-
surements were made using a measurement tool in
Vevo 770 v.2.2.3 software (Visualsonics Inc., Toronto,
ON, Canada). For MRI, a full width at half maximum
(FWHM) method was used in ImageJ software (Version
1.42q, National Institutes of Health, Bethesda, MD).
RECIST and WHO analyses were performed according
to their definitions. For volume accuracy, the equation
V=π/6·a·b·c where a, b and c are diameters in three
perpendicular dimensions was used [27].
Gammex/UTHSCSA Mark 2 phantom
After testing the Gammex/UTHSCSA Mark 1 phantom
in multiple imaging modalities, the phantom was rede-
signed based on the number of target lesions (five per
organ) required by RECIST and the dimensions neces-
sary for use in preclinical scanners (Figure 2 a and 2b,
Table 1). The phantom consisted of five tumor-simulat-
ing test objects with different diameters of measurement
calibration standards: A. Diameter - low contrast
spheres (2, 4, 7, 10 and 14 mm) and B. Volume - low
contrast spheres with volumes 4.2 to 1436.8 mm
3.T h e
sizes of test objects were chosen based on the following
reasons: 2 mm is the smallest tumor size in rodent
models that can be readily palpated and 14 mm is the
maximum tumor size tolerated without perturbing influ-
ence by host animal physiology.
US, CT and MR images were acquired and the size of
test objects in the phantom for the US and MR images
was measured to calculate RECIST, WHO and volume
as described for the Mark 1 phantom (Figure 2 c-e,
Table 2).
UTHSCSA multimodality tumor measurement phantom
A new multimodality tumor measurement phantom
was constructed to improve the contrast and geometry
of Gammex/UTHSCSA Mark 1 and 2 phantoms (Fig-
u r e3aa n d3 b ,T a b l e1 ) .T h ep h a n t o mh a df i v et e s t
objects of 2, 4, 7, 10 and 14 mm as Gammex/
UTHSCSA Mark 2 phantom but was constructed with
smaller dimensions (length × width × depth of 11.5 cm
× 3.8 cm × 2.4 cm) so that it would fit any preclinical
scanner. The phantom was made in house of tissue
mimicking (TM) materials based on methods devel-
oped in Dr. Ernest L. Madsen’s laboratory at the Uni-
versity of Wisconsin Madison [28] (See additional file
1: technical appendix with detailed description of
phantom construction; additional file 2: Table S1 sum-
marizing the phantom ingredients; additional file 3:
Figure S1 describing silicone mold preparation; addi-
tional file 4: Figure S2 describing silicone mold proce-
dures; and additional file 5: Figure S3 describing
phantom assembly procedures).
US, CT and MR images of the phantom were acquired
(Figure 3 c-e, Table 2). The size of test objects in the
phantom was measured to calculate RECIST, WHO and
volume for the US and MRI images as described for the
Mark 1 phantom. For CT, a FWHM method was used
in ImageJ software. For CT and MRI, contrast (%) was
calculated using the equation C = (Sbackground -S object)/
Sbackground.
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Page 2 of 10Figure 1 Gammex/UTHSCSA Mark 1 phantom. (a) Design, (b) photograph, (c) image caliper, volume, diameter and diameter depth
dependence of US images, (d) CT and (e) T1 weighted MR images of the phantom are displayed. Visualsonics US unit with 35 MHz frequency,
clinical Philips CT and clinical Philips 3T MRI units were used. The size of the phantom was too large to fit into the bore of all preclinical CT and
MR scanners.
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Linear regression analysis was performed on design
volume (NIST traceable gold standard) as a function of
measured volume of test objects for Gammex/UTHSCSA
Mark 2 phantom and the UTHSCSA multimodality
tumor measurement phantom using GraphPad Prism
software (Version 5.01, GraphPad Software Inc, San
Diego, CA). Analysis of RECIST and WHO for all three
phantoms and that of volume for Gammex/UTHSCSA
Mark 1 phantom could not be performed because two
data points were insufficient for statistical analyses. A p-
value < 0.05 was considered statistically significant.
Table 1 Comparison of Gammex/UTHSCSA Mark 1 phantom, Gammex/UTHSCSA Mark 2 phantom and UTHSCSA
multimodality tumor measurement phantom




3) 16.8 × 7.8 × 4.0 12.0 × 4.3 × 5.0 11.5 × 3.8 × 2.4
Weight (g) 537.00 308.49 101.02
Material Gammex TM materials Gammex TM materials Water-based TM materials
Components
Image Caliper Stainless steel wires at 2 mm vertical
intervals and 3 mm horizontal intervals
N/A N/A
Volume Two low contrast spheres with volumes
179.59 and 523.59 mm
3
Five low contrast spheres with volumes 4.2 to 1436.8
mm
3
Five low contrast spheres
with volumes 4.2 to 1436.8
mm
3
Diameter Low contrast cylinders (5 to 10 mm by 0.5
mm intervals)
Five low contrast spheres (2, 4, 7, 10 and 14 mm) Five low contrast spheres (2,




2 mm-cylinders from 2 to 15 mm depth N/A N/A
Problems
Size Too large to fit into bore of preclinical CT
and MR scanners.
Too large to fit into bore of some preclinical MR units. Adequate.
CT contrast Poor. Poor due to lack of contrast agent in TM materials. Adequate.
Artifact in US Reverberation artifacts due to the surface
membrane material chosen for phantom.
Distortion of spheres was evident because the lateral
resolution was significant in areas far from focal length.
Slight reverberation artifacts
were observed.
Table 2 Imaging modalities and protocols used in this study
Gammex/UTHSCSA Mark 1 phantom Gammex/UTHSCSA Mark 2 phantom UTHSCSA Multimodality
tumor measurement
phantom
US Vevo 770™ -120 high frequency system(Visualsonics
Inc. Toronto, ON, Canada)
Vevo 770™ -120 high frequency system
(Visualsonics Inc. Toronto, ON, Canada)
Vevo 770™ -120 high
frequency system(Visualsonics
Inc. Toronto, ON, Canada)
Scanhead RMV 703, 35 MHz center frequency, 10
mm focal length
Scanhead RMV 703, 35 MHz center frequency,
10 mm focal length
Scanhead RMV 703 35 MHz
center frequency, 10 mm focal
length
Resolution Axial: 50 μ, Lateral: 110 μ Axial: 50 μ, Lateral: 110 μ Axial: 50 μ, Lateral: 110 μ
CT Brilliance 64-slice scanner (Philips Healthcare,
Andover, MA)




Tube voltage: 120 kV, Tube current: 133 mA,
Exposure time: 0.75 s, CTDIvol : 21.4 mGy
Tube voltage: 75 kV, Tube current: 185 μA,
Acquisition time: 60 s
Tube voltage: 75 kV, Tube
current: 185 μA, Acquisition
time: 60 s
Resolution 0.35 × 0.35 × 1.00 mm
3 0.17 × 0.17 × 0.17 mm
3 0.17 × 0.17 × 0.17 mm
3
MRI Achieva 3.0T scanner (Philips Healthcare, Andover,
MA)
Intera 1.5T scanner (Philips Healthcare, Andover,
MA)
7.0T scanner (Bruker BioSpin
MRI GmbH, Ettlingen, Germany)
Surface coil Turbo spin echo T1 weighted images TR
= 1121 ms, TE = 4.63 ms, echo train factor = 5 and
number of average = 10
Head coil 3D FFE T1 weighted images TR =
8.59 ms, TE = 4.19 ms, echo train factor = 0
and number of average = 24
Bruker Volume coil 3D Turbo
RARE
Resolution 0.94 × 0.94 × 5.00 mm
3 0.75 × 0.75 × 2.00 mm
3 0.13 × 0.20 × 0.23 mm
3
* FFE - Fast Field Echo
* RARE - Rapid Acquisition with Relaxation Enhancement
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Page 4 of 10Figure 2 Gammex/UTHSCSA Mark 2 phantom. (a) Design, (b) photograph, (c) US, (d) micro-CT and (e) T1 weighted MR images of the
phantom are shown. Visualsonics US unit with 35 MHz frequency, Gamma-Medica Ideas micro-CT unit and clinical Philips 1.5 T MRI unit were
used. Sphere distortion in US images and poor contrast in CT images show limitations of the phantom (red arrow).
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Multimodality images of Gammex/UTHSCSA Mark 1
phantom, Gammex/UTHSCSA Mark 2 phantom, and
UTHSCSA multimodality tumor measurement phantom
Table 1 summarizes the size, weight, material, compo-
nents and problems of Gammex/UTHSCSA Mark 1
phantom, Gammex/UTHSCSA Mark 2 phantom, and
UTHSCSA multimodality tumor measurement phantom.
Figure 1 c - e depicts US, CT and MR images of Gam-
mex/UTHSCSA Mark 1 phantom. During testing of the
Mark 1 phantom, several problems became evident.
First, although the Mark 1 phantom was initially
designed to fit into preclinical scanners, it was too large
to fit into the bore of preclinical mouse CT and MR
units. Second, CT contrast in the two spheres for
volume accuracy needed to be improved for accurate
size measurement. Third, reverberation in the surface of
the phantom interfered with US imaging.
In the Gammex/UTHSCSA Mark 2 phantom, the
design was simplified based on the number (five per
organ) of target lesions required by RECIST as shown in
Figure 2. The UTHSCSA multimodality tumor measure-
ment phantom had the same structure as the Mark 2
phantom but the geometry and contrast of the phantom
Figure 3 UTHSCSA multimodality tumor measurement phantom. (a) Design, (b) photograph, (c) US, (d) micro-CT and (e) T2 weighted MR
images of the phantom are shown. Visualsonics US unit with 35 MHz frequency, Gamma-Medica Ideas micro-CT unit and Bruker 7.0 T MRI unit
were used. Artifacts, size and contrast problems noted with Gammex/UTHSCSA Mark 1 and Mark 2 phantoms were solved with this phantom.
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Page 6 of 10were improved by reducing the size of the phantom and
adding contrast agents to the TM materials as displayed
in Figure 3. Tumor-simulating test objects appeared dar-
ker than background in all three images and the con-
trast between test objects and background (CT: 9.67%
and MRI: 25.15%) was sufficient to distinguish test
objects and measure their size. Except for a small rever-
beration close to the surface in the US images, no arti-
facts were evident for the UTHSCSA multimodality
tumor measurement phantom.
Size measurement in Gammex/UTHSCSA Mark 1,
Gammex/UTHSCSA Mark 2 phantom, and UTHSCSA
multimodality tumor measurement phantom
RECIST, WHO and volume analyses for two spheres
from US and MR images of the Gammex/UTHSCSA
Mark 1 phantom are displayed in Table 3. For the Mark
1 phantom, smaller errors were determined for RECIST
for both US (1.73 ± 0.44%) and MRI (-2.65 ± 3.74%)
compared with WHO (US, -4.75 ± 1.30%; MRI, -7.56 ±
6.52%), with MRI errors larger than for US by both
RECIST and WHO. For volume analysis, MRI errors
were larger than for US for both the 7 mm and 10 mm
test objects. RECIST, WHO and volume analyses for CT
were not determined due to inadequate CT contrast.
Table 4 shows RECIST, WHO and volume analyses
for five test objects from US and MR images of the
Gammex/UTHSCSA Mark 2 phantom. Measurements
from CT images were not determined due to the same
reasons as mentioned for the Mark 1 phantom (Figure 2
d). For US, RECIST (5.66 ± 1.41%) had larger errors
than WHO (-0.16 ± 1.32%). For MRI, RECIST and
WHO analyses showed small errors ranging from 0.39 ±
2.54% for RECIST to -2.05 ± 2.79% for WHO. Volumes
calculated from US images had larger errors (range of
-5.69 ± 1.59% to 7.29 ± 5.65%) for smaller test objects
(2, 4 and 7 mm) which improved with the analyses of
the 10 mm (3.99 ± 2.03%) and 14 mm (1.21 ± 0.66%)
test objects. Volume analysis from MR images showed
similar features to that for US but had much larger
errors (range of -21.81 ± 66.60% to 11.86 ± 21.62%) for
smaller test objects (2, 4 and 7 mm). For Mark 2 phan-
tom, tumor volume measured by US and MRI correlated
(p < 0.0001) with design volume (Table 4). The best fits
f o rU Sa n dM R Iv e r s u sd e s i g nv o l u m ew e r el i n ey=
1.014 ± 0.009x - 0.152 ± 6.341 (R
2 = 0.9998; p < 0.0001)
and line y = 0.962 ± 0.011x - 6.665 ± 7.357 (R
2 =
0.9996; p < 0.0001), respectively.
RECIST, WHO and volume analyses for the
UTHSCSA multimodality tumor measurement phantom
are displayed in Table 5. Unlike results for the Mark 2
phantom, RECIST and WHO calculations showed
reduced errors (range of -1.47 ± 0.25% to 1.69 ± 0.33%)
for all three modalities. RECIST analysis showed smaller
errors than WHO analysis except for CT. For volume
analysis, errors were ≤ -2.84 ± 2.49% except for the 10
mm test object in MRI (-5.34 ± 0.76%) and the smallest
test object (2 mm) with errors ranging from -18.30 ±
10.65% to 5.72 ± 0.60% for CT and MRI, respectively.
For the UTHSCSA multimodality tumor measurement
phantom, US-, CT- and MRI-measured tumor volume
also correlated (p < 0.0001) with design volume (Table
5 ) .U S ,C Ta n dM R I- m e a s u r e dv o l u m ev e r s u sd e s i g n
(NIST traceable gold standard) volume had the best fit
of lines y = 0.980 ± 0.003x + 2.277 ± 2.261 (R
2 = 1.000;
p < 0.0001), y = 1.011 ± 0.004x + 0.413 ± 3.052 (R
2 =
0.9999; p < 0.0001) and y = 0.977 ± 0.008x - 1.013 ±
5.613 (R
2 = 0.9998; p < 0.0001), respectively. These
results demonstrate that technical personnel using the
phantom could quickly prove the data from all three
modalities is acceptable over the entire range of sizes
with error limits determined by the study designer by
comparing the slope and intercept values from a simple
regression analysis (Table 5).
Discussion
Previous QA phantoms constructed for size measurement
had various tumor shapes and focused predominately on
Table 3 RECIST, WHO and volume analyses from US and MR images of Gammex/UTHSCSA Mark 1 phantom
Design Image RECIST and WHO (mean ± SD (% error))
US MRI
RECIST (mm) 17.00 17.29 ± 0.08 (+1.73 ± 0.44%) 16.55 ± 0.64 (-2.65 ± 3.74%)
WHO (mm
2) 149.00 141.93 ± 1.94 (-4.75 ± 1.30%) 137.73 ± 9.72 (-7.56 ± 6.52%)
Design Image Volume (mean ± SD (% error))
US MRI
Volume (mm
3) 179.59 (7 mm sphere) 180.45 ± 7.51 (+0.48 ± 4.18%) 152.68 ± 30.81 (-14.99 ± 7.16%)
523.59 (10 mm sphere) 498.54 ± 12.60 (-4.78 ± 2.41%) 485.49 ± 31.68 (-7.28 ± 6.05%)
Mean ± standard deviation (SD) for three repeated measures and % errors in parenthesis are shown for RECIST, WHO and volume analysis. RECIST and WHO
calculations were based on their definitions. For volume calculation, an equation V=π/6·a·b·c where a, b and c are diameters in three perpendicular dimensions
was used.
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using measurement protocols unique to their institution
[15-17]. This study focused on construction of a phantom
with a simple spherical test object design based on a FDA
approved imaging biomarker (WHO criteria, RECIST) for
use with multiple preclinical imaging devices. As discussed
in Table 1, the Gammex/UTHSCSA Mark 1 and Mark 2
phantoms were too large to fit into the bore of some pre-
clinical CT and MR scanners. Since certain components of
the Mark 1 phantom such as image caliper and depth
dependence were not required for QA of tumor size mea-
surement, these features were deleted in the Mark 2 phan-
tom based on RECIST (Figure 2). Composite aluminum
poly film (Figures 1 c and 2 c) on the Mark 1 phantom
surface caused reverberation artifact in the US images that
were corrected in future phantoms by using thin compo-
site polyethylene terephthalate/aluminum/linear low den-
sity polyethylene (PET/AL/LLDPE). In addition, test
o b j e c t si nU Si m a g e so ft h eM a r k2p h a n t o md i dn o t
appear as perfect spheres compared with those in MR
Table 4 RECIST, WHO and volume analyses from US and MR images of Gammex/UTHSCSA Mark 2 phantom
Design Image RECIST and WHO (mean ± SD (% error))
US MRI
RECIST (mm) 37.00 39.09 ± 0.52 (+5.66 ± 1.41%) 37.15 ± 0.94 (+0.39 ± 2.54%)
WHO (mm
2) 365.00 355.44 ± 4.69 (-0.16 ± 1.32%) 348.69 ± 9.95 (-2.05 ± 2.79%)
Design Image Volume (mean ± SD (% error))
US MRI
Volume (mm
3) 4.19 (2 mm sphere) 4.37 ± 0.40 (+4.40 ± 9.47%) 3.28 ± 2.79 (-21.81 ± 66.60%)
33.51 (4 mm sphere) 35.93 ± 1.89 (+7.29 ± 5.65%) 37.46 ± 7.24 (+11.86 ± 21.62%)
179.59 (7 mm sphere) 169.38 ± 2.85 (-5.69 ± 1.59%) 155.43 ± 29.57 (-13.45 ± 16.46%)
523.60 (10 mm sphere) 544.50 ± 10.65 (+3.99 ± 2.03%) 484.32 ± 25.94 (-7.50 ± 4.95%)
1436.76 (14 mm sphere) 1453.39 ± 9.42 (+1.21 ± 0.66%) 1381.45 ± 32.07 (-3.80 ± 2.23%)
Slope [95% CI] 1.014 ± 0.009 [0.984 to 1.043] 0.962 ± 0.011 [0.928 to 0.996]
Intercept [95% CI] -0.152 ± 6.341 [-20.33 to 20.02] -6.665 ± 7.357 [-30.08 to 16.75]
R
2 0.9998 0.9996
p-value < 0.0001 < 0.0001
Mean ± standard deviation (SD) for three repeated measures and % errors in parenthesis are shown for RECIST, WHO and volume analysis. The same analysis
methods as described for the Mark 1 phantom were used. Slope and intercepts [95% confidence intervals], correlation coefficient (R
2) and p-value of linear
regression lines for volume of test objects also are shown.
Table 5 RECIST, WHO and volume analyses from US, CT and MR images of UTHSCSA multimodality tumor
measurement phantom
Design Image RECIST and WHO (mean ± SD (% error))
US CT MRI
RECIST (mm) 37.00 37.05 ± 0.05 (+0.13 ± 0.13%) 37.62 ± 0.12 (+1.69 ± 0.33%) 37.39 ± 0.13 (+1.05 ± 0.34%)
WHO (mm
2) 365.00 359.634 ± 0.93 (-1.47 ± 0.25%) 368.76 ± 1.47 (+1.03 ± 0.39%) 359.96 ± 2.09 (-1.38 ± 0.57%)
Image Volume (mean ± SD (% error))
US CT MRI
Volume (mm
3) 4.19 (2 mm sphere) 3.55 ± 0.00 (-15.34 ± 0.04%) 3.42 ± 0.45 (-18.30 ± 10.65%) 4.43 ± 0.03 (+5.72 ± 0.60%)
33.51 (4 mm sphere) 32.76 ± 0.33 (-2.24 ± 0.99%) 32.56 ± 0.83 (-2.84 ± 2.49%) 34.05 ± 1.24 (+1.62 ± 3.70%)
179.59 (7 mm sphere) 180.71 ± 1.71 (+0.62 ± 0.95%) 179.41 ± 4.06 (-0.10 ± 2.26%) 180.84 ± 4.25 (+0.70 ± 2.36%)
523.60 (10 mm sphere) 520.27 ± 3.19 (-0.64 ± 0.61%) 537.90 ± 4.08 (+2.73 ± 0.78%) 495.65 ± 3.97 (-5.34 ± 0.76%)
1436.76 (14 mm sphere) 1408.59 ± 5.67 (-1.96 ± 0.39%) 1450.39 ± 11.22 (+0.95 ± 0.78%) 1406.47 ± 8.16 (-2.11 ± 0.57%)
Slope [95% CI] 0.980 ± 0.003 [0.969 to 0.991] 1.011 ± 0.004 [0.997 to 1.025] 0.977 ± 0.008 [0.951 to 1.002]
Intercept [95% CI] 2.277 ± 2.261 [-4.919 to 9.472] 0.413 ± 3.052 [-9.299 to 10.12] -1.013 ± 5.613 [-18.87 to 16.85]
R
2 1.000 0.9999 0.9998
p-value <0.0001 <0.0001 <0.0001
Mean ± standard deviation (SD) for three repeated measures and % errors in parenthesis are shown for RECIST, WHO and volume analyses. The same analysis
methods as described for the Mark 1 and Mark 2 phantoms were used. Slope and intercepts [95% confidence intervals], correlation coefficient (R
2) and p-value of
linear regression lines for volume of test objects also are shown.
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Page 8 of 10images (Figure 2c). The beam dispersion in the region dee-
per than focal depth created distortion in the spheres
(overestimated diameter in horizontal directions and
underestimated diameter in depth). The contrast in CT
images of both phantoms was not sufficient to make size
measurements (Figure 1 d and 2 d).
In the UTHSCSA multimodality tumor measurement
phantom, size, distortion and contrast problems were
solved for the images acquired with all three modalities
(Figure 3 c-e). First, the diameter of the tumor measure-
ment phantom was reduced to fit within the bore of all
preclinical scanners. Second, the center of test objects
was designed to be set above the focal depth (10 mm
for 35 MHz transducer) to avoid distortion. Third, bar-
ium sulfate was used for pronounced CT contrast. As a
result, test object measurements were improved for the
UTHSCSA multimodality tumor measurement phantom.
For all imaging modalities, RECIST and WHO errors
were reduced for UTHSCSA multimodality tumor mea-
surement phantom (≤1.69 ± 0.33%) compared with both
M a r k1( ≤ -7.56 ± 6.52%) and Mark 2 (≤ 5.66 ± 1.41%)
phantoms.
RECIST values were more accurate than WHO values
for the UTHSCSA multimodality tumor measurement
phantom except for CT. This result corresponded to the
fact that WHO criteria are known to give higher risk of
measurement error and overestimation of response rates
[9]. Volume calculation of the smallest test object (2
mm) in the UTHSCSA multimodality tumor measure-
ment phantom had the largest errors of -15.34 ± 0.04%
and -18.30 ± 10.65% for US and CT, respectively, and
errors were reduced for larger test objects (≤ -2.84 ±
2.49%) except for 10 mm sphere by MRI (-5.34 ± 0.76%)
(Table 5). This explains why small tumors smaller than
or equal to 2 mm in preclinical and clinical tumor mod-
els cannot be measured with high accuracy.
Conclusions
The UTHSCSA multimodality tumor measurement
phantom design and construction methods provide ade-
quate image quality for validating tumor size measure-
ment in three commonly used preclinical imaging
modalities (US, CT and MRI). This tumor measurement
phantom provides a potential QA tool for monitoring
radiologic assessment of tumor size change in future
multi-institutional studies requiring integration of data
from disparate sources and devices.
Additional material
Additional file 1: Lee et al Technical Appendix.pdf. Technical
Appendix is a detailed description of the construction of the UTHSCSA
multimodality tumor measurement phantom.
Additional file 2: Lee et al Table S1.pdf. Summary of the ingredients
used to construct the UTHSCSA multimodality tumor measurement
phantom.
Additional file 3: Lee et al Figure S1.tiff. Preparation for making
silicone molds to cast test objects of UTHSCSA multimodality tumor
measurement phantom. (A) Two identical base plates, (B) spacer pairs, (C)
steel balls, (D) procedure for gluing steel balls, and (E) two identical
mirror image base plates with steel balls.
Additional file 4: Lee et al Figure S2.tiff. Materials and procedures for
making silicone molds. (A) Acrylic rods with 1 mm tips, (B) base plates
with fences, alignment rods, acrylic rods, and (C) mold after addition of
silicone rubber compound.
Additional file 5: Lee et al Figure S3.tiff. Procedures for preparing
UTHSCSA multimodality tumor measurement phantom using silicone
molds. (A) Nylon thread was attached to silicone mold and the molds
were adhered with silicone grease. (B) Milk mixture was degassed using
house vacuum. (C) After casting test objects in the mold, test objects
were mounted in an acrylic container. (D) The top of the container was
sealed with surface membrane. (E) Background material was poured into
the container. (F) The assembled phantom was placed in rotator and
rotated to prevent gravitational sedimentation of tissue mimicking
materials.
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